

## Human B7-2 (CD86) Protein (C-Fc-Avi)

<b>Catalog Number:</b>	817501, 817502
<b>Size:</b>	25 ug, 100 ug
<b>Target Name:</b>	CD86, B7-2, B70, CD28LG2
<b>Regulatory Status:</b>	RUO

### PRODUCT DETAILS

---

<b>Application:</b>	ELISA, BLI
<b>Format:</b>	Liquid, Purified
<b>Expression Host:</b>	CHO
<b>Species:</b>	Human
<b>Sources:</b>	Recombinant Human B7-2 (CD86) (Leu20-Pro247) with C-terminus Fc-Avi-tag is expressed in CHO cell.
<b>Accession Number:</b>	P05408
<b>Molecular Weight:</b>	The protein has a predicted molecular weight of 54.2 kDa. Under DTT-reducing conditions, it migrates at approximately 75 kDa on SDS-PAGE.
<b>Affinity Tag:</b>	C-Fc-Avi
<b>Purity:</b>	>95% based on SDS-PAGE under reducing condition
<b>Formulation:</b>	1xPBS buffer, pH7.4, 0.22 µm filtered
<b>Endotoxin level:</b>	Not tested
<b>Protein Concentration:</b>	25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.
<b>Storage and Handling:</b>	Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ -70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.


### BACKGROUND INFORMATION

---


CD86 (B7-2) is a member of the immunoglobulin superfamily, expressed predominantly as a monomer on cell surfaces, and interacts with co-stimulatory receptors CD28 and CTLA-4 on T cells. This interaction regulates T cell activation, tolerance, cytokine production, and the generation of cytotoxic T lymphocytes (CTL). CD86 plays a critical role in promoting B and T helper cell interactions, supporting B cell proliferation and IgG secretion, particularly in B cell lymphomas. It also contributes to the development of a mature antigen-presenting cell (APC) repertoire, enhancing APC function and survival. CD86 is involved in chronic hemodialysis, allergic pulmonary inflammation, arthritis, and antiviral responses, positioning it as a potential target for immune

therapies.

**PRODUCT DATA**



Human B7-2 (CD86) (C-Fc-Avi) on SDS-PAGE under reducing condition (P+) and non-reducing condition (P-). The gel was stained for 1 hour with BlinkBlue (catalog 700102). The purity of this protein appears to be greater than 95% based on reducing conditions.



Human CTLA4 (C-His) is coated at 10ug/mL (1ug/well). Human B7-2 (CD86) (C-Fc-Avi) can bind human CTLA-4 in the dose dependent manner with ED50 in the range of 10-30 ng/mL.

This product is supplied subject to the terms and conditions at [www.innocyto.com/web/terms.php](http://www.innocyto.com/web/terms.php) and may only be used as provided in the stated terms. Products are for Research Use Only.